Inactive Instrument

Highlights Spectrum Pharmaceuticals, Inc.

Equities

SPPI

US84763A1088

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Assertio Therapeutics Completes Acquisition of Spectrum Pharmaceuticals, Reports Lower Q2 Adjusted Earnings	23-08-04	MT
Assertio Holdings Closes Acquisition of Spectrum Pharmaceuticals	23-08-01	MT
Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).	23-07-30	CI
Spectrum Pharmaceuticals Regains Nasdaq Compliance	23-05-17	MT
Earnings Flash (SPPI) SPECTRUM PHARMACEUTICALS Reports Q1 Revenue $15.6M	23-05-09	MT
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Assertio Holdings to Acquire Spectrum Pharmaceuticals	23-04-25	MT
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Earnings Flash (SPPI) SPECTRUM PHARMACEUTICALS Posts Q4 Revenue $10.1M	23-03-22	MT
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-22	CI
Alembic Pharmaceuticals Gets Final US FDA for Fluorouracil Injection	23-03-06	MT
Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection from U.S. Centers for Medicare & Medicaid Services	23-02-08	CI
Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022	23-01-31	CI
Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors	22-12-06	CI
Fed Rate Policy Outlook Buoys Exchange-Traded Funds, Equities Futures Premarket Friday	22-11-25	MT
Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection	22-11-25	CI
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection	22-10-21	CI
Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting	22-09-22	CI
U.S. FDA staff raises concerns on Spectrum Pharma's cancer drug	22-09-20	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spectrum Pharmaceuticals, Inc.

Equities

SPPI

US84763A1088

Highlights

Filters